Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Recruiting now · Phase 2
Conditions studied: Metastatic Urothelial Cancer
In brief
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Key facts
- Study ID
- NCT03547973
- Run by
- Gilead Sciences
- People needed
- 827
- Starts
- 2018-08-13
- Expected to finish
- 2030-04-01
- Last updated by the study team
- 2026-03-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Houston Methodist Hospital, Houston Methodist Cancer Center — Houston, Texas, United States (enrolling)
- Virginia Oncology Associates — Hampton, Virginia, United States (enrolling)
- Thompson Oncology Group - Knoxville West — Knoxville, Tennessee, United States (enrolling)
- Henry-Joyce Cancer Clinic — Nashville, Tennessee, United States (enrolling)
- Mays Cancer Center — San Antonio, Texas, United States (enrolling)
- University of Utah - Huntsman Cancer Hospital (IP Shipping Address) — Salt Lake City, Utah, United States (enrolling)
- Rocky Mountain Cancer Centers — Littleton, Colorado, United States (enrolling)
- Medical University of Southern Carolina — Charleston, South Carolina, United States (enrolling)
- The University of Arizona Cancer Center-North Campus — Tucson, Arizona, United States (enrolling)
- University of Illinois Cancer Center — Chicago, Illinois, United States (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- Southern Illinois University School of Medicine, Simmons Cancer Institute — Springfield, Illinois, United States (enrolling)
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States (enrolling)
- Norton Cancer Institute, Downtown — Louisville, Kentucky, United States (enrolling)
- Woodlands Medical Specialists, PA — Pensacola, Florida, United States (enrolling)
- University of Michigan — Ann Arbor, Michigan, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
- Smilow Cancer Hospital at Yale-New Haven — New Haven, Connecticut, United States (enrolling)
- Roswell Park Cancer Institute — Buffalo, New York, United States (enrolling)
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York, United States (enrolling)
- Drug Shipping Address: New York-Presbyterian Hospital — New York, New York, United States (enrolling)
- University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
- St. Luke's Hosptial - Bethlehem Campus — Easton, Pennsylvania, United States (enrolling)
- Oncology Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Roanoke, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.